Who is sponsoring FACILITATE-HF?

FACILITATE-HF is sponsored by Juntendo University.

What condition does FACILITATE-HF study?

FACILITATE-HF studies Acute Heart Failure.

What drugs are being tested in FACILITATE-HF?

Interventions: Finerenone Oral Tablet, Finerenone Placebo.

What is the status of FACILITATE-HF?

FACILITATE-HF is currently RECRUITING.

Last reviewed 2026-02-08 · How we verify

Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure (FACILITATE-HF)

NCT07397650 Phase 4 RECRUITING

FACILITATE-HF is a multicenter, randomized, double-blind, placebo-controlled trial designed to determine whether initiation of finerenone during the early phase of hospitalization has beneficial effects in patients with AHF who have left ventricular ejection fraction 40% or more.

Details

Lead sponsor	Juntendo University
Phase	Phase 4
Status	RECRUITING
Enrolment	550
Start date	2026-02
Completion	2028-09-30

Conditions

Acute Heart Failure

Interventions

Finerenone Oral Tablet
Finerenone Placebo

Primary outcomes

A hierarchical composite endpoint of death and worsening heart failure — Up to 12 weeks
A hierarchical composite endpoint consisting of death, worsening HF during hospitalization, HF rehospitalization, worsening HF after discharge requiring IV diuretic or sustained intensification of oral therapy, and change in N-terminal pro-B-type natriuretic peptide levels at 12 weeks as assessed using a win ratio

Countries

Japan